Literature DB >> 15751925

United Arab Emirates National Newborn Screening Programme: an evaluation 1998-2000.

H al-Hosani1, M Salah, D Saade, H Osman, J al-Zahid.   

Abstract

To evaluate the United Arab Emirate National Newborn Screening Programme we compared coverage, timeliness of programme indicators (age at sampling, recall and treatment initiation, timing of specimen delivery and laboratory results) and specimen quality with international standards. Recall rate, sensitivity, specificity, positive predictive values and relative incidence rates for phenylketonuria (PKU) and congenital hypothyroidism (CH) were calculated. Investigations for hypothyroidism included thyroid function studies (T3, T4, fT4 and TSH), technetium-99m thyroid scan when possible and thyroglobulin and thyroid antibodies when indicated. PKU investigations included plasma amino acids and measurement of biopterin defects. In the 6 years before December 2000, 138,718 neonates were screened. Relative incidences for CH and for classic PKU were 1:1570 and 1:20,050 respectively.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15751925

Source DB:  PubMed          Journal:  East Mediterr Health J        ISSN: 1020-3397            Impact factor:   1.628


  10 in total

1.  Newborn screening: experiences in the Middle East and North Africa.

Authors:  A A Saadallah; M S Rashed
Journal:  J Inherit Metab Dis       Date:  2007-08-15       Impact factor: 4.982

2.  Translational Genomics in Low- and Middle-Income Countries: Opportunities and Challenges.

Authors:  Fasil Tekola-Ayele; Charles N Rotimi
Journal:  Public Health Genomics       Date:  2015-06-26       Impact factor: 2.000

3.  Next-generation community genetics for low- and middle-income countries.

Authors:  Stephen F Kingsmore; John D Lantos; Darrell L Dinwiddie; Neil A Miller; Sarah E Soden; Emily G Farrow; Carol J Saunders
Journal:  Genome Med       Date:  2012-03-29       Impact factor: 11.117

4.  Detection of Inborn Errors of Metabolism using Tandem Mass Spectrometry among High-risk Omani Patients.

Authors:  Sulaiman Al Riyami; Matar Al Maney; Surendra Nath Joshi; Riad Bayoumi
Journal:  Oman Med J       Date:  2012-11

5.  Mutation Spectrum and Birth Prevalence of Inborn Errors of Metabolism among Emiratis: A study from Tawam Hospital Metabolic Center, United Arab Emirates.

Authors:  Aisha Al-Shamsi; Jozef L Hertecant; Sania Al-Hamad; Abdul-Kader Souid; Fatma Al-Jasmi
Journal:  Sultan Qaboos Univ Med J       Date:  2014-01-27

6.  Incidence of neonatal hyperphenylalaninemia in fars province, South iran.

Authors:  Hamdollah Karamifar; Mahtab Ordoei; Zohreh Karamizadeh; Gholam Hossein Amirhakimi
Journal:  Iran J Pediatr       Date:  2010-06       Impact factor: 0.364

Review 7.  The Prevalence of Phenylketonuria in Arab Countries, Turkey, and Iran: A Systematic Review.

Authors:  Ashraf El-Metwally; Lujane Yousef Al-Ahaidib; Alaa Ayman Sunqurah; Khaled Al-Surimi; Mowafa Househ; Ali Alshehri; Omar B Da'ar; Hira Abdul Razzak; Ali Nasser AlOdaib
Journal:  Biomed Res Int       Date:  2018-04-18       Impact factor: 3.411

8.  Reference Standards for Newborn Screening of Metabolic Disorders by Tandem Mass Spectrometry: A Nationwide Study on Millions of Chinese Neonatal Populations.

Authors:  Falin He; Rulai Yang; Xinwen Huang; Yaping Tian; Xiaofang Pei; Mary Kathryn Bohn; Lin Zou; Yan Wang; Haibo Li; Ting Wang; Maosheng Gu; Tao Jiang; Xigui Chen; Hui Zou; Hongwei Wei; Weibing Tian; Tian Tang; Khosrow Adeli; Zhiguo Wang
Journal:  Front Mol Biosci       Date:  2021-12-16

9.  Indicators of newborn screening for congenital hypothyroidism in Sri Lanka: program challenges and way forward.

Authors:  Manjula Hettiarachchi; Sujeewa Amarasena
Journal:  BMC Health Serv Res       Date:  2014-09-12       Impact factor: 2.655

10.  Observations on the health of infants at a time of rapid societal change: a longitudinal study from birth to fifteen months in Abu Dhabi.

Authors:  Hazel Gardner; Katherine Green; Andrew S Gardner; Donna Geddes
Journal:  BMC Pediatr       Date:  2018-02-07       Impact factor: 2.125

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.